Table 2. Survival difference between diffuse large B-cell lymphoma subgroups.
GCB: germinal center B-cell-like; non-GC: non-germinal center; NR: Not reported; HD-MTX: high-dose methotrexate (>3g/m2); Ara-C: cytosine arabinoside; TMZ: temozolomide; RT: radiotherapy; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone
| First author (year) | No. cases | Median OS (months) | Median age (range) |
Treatment |
|---|---|---|---|---|
| Liu (2017) | 89 | 45.3 | 56 (11-85) | HD-MTX + Ara-C or HD-MTX + TMZ |
| GCB | 18 | *NR | ||
| non-GC | 71 | *NR | ||
| Aki (2013) | 35 | NR | 52 (21-85) | Unspecified: some were treated with chemotherapy (NR) + RT or chemotherapy alone |
| GCB | 6 | 19 | ||
| non-GC | 29 | 17 | ||
| Hattab (2010) | 31 | NR | 62 (13-81) | Most were treated with HD-MTX and steroids, but given the retrospective nature, some treatment regimens were unknown |
| GCB | 5 | 2.5 | ||
| non-GC | 26 | 7.4 | ||
| Raoux (2010) | 39 | 5.3 | 67 (49-83) | 19pts with chemotherapy and RT, 10pts with RT alone, 6pts with chemotherapy alone, 4pts untreated |
| GCB | 13 | *NR | ||
| non-GC | 26 | *NR | ||
| Momota (2010) | 27 | Not reached | 63 (26-78) | All pts received HD-MTX; 25/27 pts received RT |
| GCB | 1 | N/A | ||
| non-GC | 22 | N/A | ||
| Lin (2006) | 51 | 13.7 | 62 (16-82) | 29 pts with HD-MTX, 1 pt with CHOP, 15 pts with RT, 6 pts with supportive care |
| GCB | 7 | 34.5 | ||
| non-GC | 22 | 11 | ||
| Camilleri-Broet (2006) | 82 | 42 | 60 (23-80) | HD-MTX |
| GCB | 3 | *NR | ||
| non-GC | 79 | *NR |